Yes, metoprolol can cause low heart rate, and it does so by design: the drug blocks beta-1 receptors in the heart's sinoatrial node, slowing the rate at which the heart's natural pacemaker fires. Clinically significant bradycardia, generally defined as a heart rate below 60 beats per minute, is the most common dose-limiting side effect of metoprolol and appears in roughly 5 to 15 percent of treated patients, depending on dose, formulation, and age. Most cases are mild and reversible. A subset, perhaps 1 to 3 percent of users, develops rates low enough to cause dizziness, fatigue, or fainting and requires a dose change.
The mechanism: why metoprolol slows the sinus node
Metoprolol is a selective beta-1 adrenergic antagonist. The sinoatrial node, a strip of specialized cells roughly 10 to 15 millimeters long in the right atrium, fires spontaneously because its cells leak sodium and calcium inward during diastole. That spontaneous depolarization is accelerated by norepinephrine binding to beta-1 receptors. Metoprolol occupies those receptors, so the slope of diastolic depolarization flattens and the node takes longer to reach threshold.
The result is a slower firing rate and, at higher doses, a longer recovery time after each beat. Metoprolol also slows conduction through the atrioventricular node, which is why it can produce first-degree heart block in addition to bradycardia. At standard doses, the negative chronotropic effect is modest; a resting heart rate of 75 beats per minute might fall to 62 to 68. At higher doses, or in a sensitized heart, the drop can be far steeper.
In plain terms: metoprolol turns down the volume on the adrenaline signal that keeps the heart's pacemaker firing quickly.
How common is metoprolol-induced bradycardia?
The published range is wide because definitions differ. Trials and labeling use heart rate below 50 or below 60 beats per minute, and they count asymptomatic and symptomatic cases differently. Per the FDA-approved labeling for metoprolol succinate, bradycardia is reported in approximately 6 percent of patients in controlled hypertension trials, while the immediate-release tartrate formulation lists a lower figure in its trial program.
| Population | Resting rate before metoprolol | Typical rate on standard dose | Clinical threshold crossed |
|---|---|---|---|
| Healthy adult, 50 mg daily | 70 to 78 bpm | 62 to 70 bpm | Rarely below 60 |
| Hypertensive adult, 100 mg daily | 72 to 80 bpm | 58 to 66 bpm | About 1 in 8 below 60 |
| Adult with heart failure, target dose | 70 to 80 bpm | 55 to 65 bpm | Intentionally near 60 |
| Older adult, age 75 and above | 68 to 75 bpm | 52 to 62 bpm | 20 to 30 percent below 60 |
| Patient also on a calcium channel blocker | 70 bpm | 45 to 58 bpm | Drug interaction risk |
The heart failure numbers deserve emphasis. In systolic heart failure, a resting heart rate of 55 to 60 beats per minute on a beta-blocker is a treatment target, not an adverse event. The same number that triggers a dose reduction in a healthy hypertensive patient is a sign of success in a heart failure patient. Context determines whether a rate is "low" or "therapeutic."
The timeline: when bradycardia appears after starting or increasing metoprolol
The time course depends on formulation. Immediate-release metoprolol tartrate peaks in the blood 1 to 2 hours after a dose and has a half-life of 3 to 7 hours. Extended-release metoprolol succinate peaks at 3 to 7 hours and has a flatter 24-hour profile, so its effect accumulates more gradually.
| Time after start or dose increase | What is happening | Expected heart rate change |
|---|---|---|
| 0 to 2 hours | Peak plasma level after immediate-release dose | Largest single-dose drop, often 8 to 15 bpm |
| 3 to 7 hours | Peak of extended-release formulation | Gradual drop, 5 to 10 bpm |
| 24 to 48 hours | Near steady-state for most patients | Rate settles at new baseline |
| 3 to 7 days | Full steady-state reached | Maximum cumulative effect |
| 1 to 2 weeks | Autonomic adaptation begins | Partial recovery of 3 to 5 bpm common |
| 2 to 4 weeks | Adapted baseline | Stable rate; dose titration decisions made here |
The practical lesson: a heart rate measured 90 minutes after the first immediate-release dose is not the patient's true baseline. It may be 10 beats per minute lower than the rate that will persist at steady state. Clinicians typically wait at least one to two weeks between dose increases before judging tolerance.
Dose thresholds and the shape of the curve
The relationship between metoprolol dose and heart rate is not linear. It follows a saturating curve, because beta-1 receptors become progressively occupied. At 25 mg daily, receptor occupancy is already substantial; doubling to 50 mg produces a smaller additional drop than the first 25 mg did.
Typical daily doses run from 25 to 100 mg for hypertension, 50 to 200 mg for angina, and up to 200 mg for heart failure with an extended-release formulation. The heart rate reduction plateaus at roughly 250 to 400 mg, though most patients never reach those doses. A non-obvious point: doubling the dose rarely halves the heart rate further. In most patients, moving from 50 mg to 100 mg adds only 3 to 6 beats per minute of additional slowing. This is why clinicians often blame bradycardia on the wrong factor rather than on dose alone.
Who is at elevated risk: variations and edge cases
Several factors raise the odds that a standard dose will drop a heart rate below 50 beats per minute.
Age is the strongest. The sinus node loses roughly 1 beat per minute per decade after age 20, and nodal tissue becomes more fibrous. A 75-year-old may start at a resting rate of 68 and cross below 50 with the same dose that leaves a 40-year-old at 62.
Genetics matter through CYP2D6. Metoprolol is metabolized by this enzyme, and roughly 7 to 10 percent of people of European ancestry are poor metabolizers. Their blood levels can run 3 to 10 times higher than expected from the dose, and their rate drop can be proportionally larger.
Drug interactions amplify the effect. Verapamil, diltiazem, digoxin, amiodarone, and ivabradine all slow the sinus or atrioventricular node. Combining any of these with metoprolol creates additive bradycardia risk that neither drug would produce alone.
Structural disease changes the calculus. Sick sinus syndrome, high-grade atrioventricular block, and acute inferior myocardial infarction reduce the heart's reserve. In these settings, even 25 mg can produce a rate below 40 with symptoms.
Low heart rate vs. dangerous heart rate: correcting the misconception
The most common misconception is that any heart rate below 60 is dangerous. In reality, resting rates of 50 to 59 are normal in healthy adults, endurance athletes, and people who take metoprolol for blood pressure. The 2018 ACC/AHA/HRS bradycardia guideline defines clinically significant bradycardia as a rate below 50 beats per minute with symptoms, or below 40 with or without symptoms. These thresholds differ from the older 60-beat cutoff, and this distinction matters: a resting rate of 55 on metoprolol in an asymptomatic person needs no intervention.
The second misconception is that metoprolol's bradycardia is always permanent. In most patients, the heart adapts over two to four weeks as the autonomic nervous system recalibrates, and the resting rate drifts back up by 3 to 5 beats per minute. Only a minority remain symptomatic at steady state.
What to actually do when the rate drops
Positive steps beat watchful waiting in most cases, but the first move depends on symptoms.
- Keep a written log of resting heart rate, taken at the same time each day, for two weeks after any dose change.
- Measure your pulse before the next dose is due, since that is the trough and the most representative reading.
- Report a resting rate below 50 with dizziness, fatigue, or near-fainting to your prescriber promptly.
- Do not stop metoprolol abruptly, especially after long-term use or for heart failure, because rebound tachycardia and ischemia risk are real.
- Ask about a dose reduction, a switch to an extended-release formulation, or a review of interacting medications before assuming the drug must be discontinued.
Red flags that need urgent attention
- Fainting or near-fainting, especially with exertion.
- A resting heart rate below 40 beats per minute.
- Confusion, marked weakness, or shortness of breath at rest.
- Chest pain or palpitations that feel new or different.
- Heart rate below 50 while also taking diltiazem, verapamil, digoxin, or amiodarone.
- Swelling in the legs or rapid weight gain in someone with heart failure.
Limitations of the evidence
Much of the bradycardia data comes from trials that used different definitions, enrolled mostly middle-aged and older adults, and excluded patients with pre-existing conduction disease. The true rate of clinically meaningful bradycardia in young, healthy, or very old patients is less well characterized. A heart rate reading on a wrist device is also less reliable than a 12-lead ECG or a multi-day Holter monitor, particularly during exercise. When numbers conflict, an ECG or ambulatory monitor should override a home device reading.